A8D Intrinsic Valuation and Fundamental Analysis - AB Science SA

Watchlist Manager

Watchlist

Price: 0.553 EUR -3.66% Market Closed

Market Cap: €29m

A	AB Science SA F:A8D	FR
S	Standard Chartered PLC XMUN:STD	UK

Intrinsic Value

There is not enough data to reliably calculate the intrinsic value for AB Science SA.

Do our valuations actually work? See backtest results .

Fundamental Analysis

What AB Science Does

Pharmaceuticals Health Care

AB Science SA is a French biopharmaceutical company that develops medicines aimed at diseases where the immune system, inflammation, or certain cancers play a major role. Its work centers on small-molecule drug candidates, especially mast-cell kinase inhibitors, that are designed to change how a disease progresses rather than just treat symptoms. The company does not sell a broad portfolio of commercial drugs; it focuses on research, clinical testing, and regulatory development of a few lead compounds.

Headquarters: France FR
Employees: 36
IPO date: Apr 21, 2010

Read the full company overview

How AB Science makes money

Drug development

AB Science SA develops and tests small-molecule medicines, especially its lead drug candidates built to act on specific biological targets in cancer, inflammatory diseases, and some nervous system disorders. The company runs laboratory work, clinical studies, and regulatory filing work to advance these medicines toward approval.

Customers: Patients, through doctors and hospitals that prescribe the medicines if they are approved, and pharmaceutical partners that may license or develop the candidates with AB Science.
Revenue Model: It aims to earn money from licensing deals, development partnerships, milestone payments, and future sales or royalties if a drug reaches the market.

View Company Overview